TMEM120A Knockout cell line (T24)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

TMEM120A (transmembrane protein 120A) encodes a membrane-associated protein located in the endoplasmic reticulum and plasma membrane. It has coenzyme A-binding activity and is involved in antiviral innate immune responses, adipocyte differentiation, and protein complex oligomerization. TMEM120A therefore contributes to membrane-associated cellular regulation and metabolic or differentiation-related processes.

The T24 cell line was established in 1970 from a primary grade III transitional cell carcinoma (urothelial carcinoma) of the urinary bladder from an 81-year-old female patient. This human bladder carcinoma cell line is widely characterized and has been reported to carry HRAS and p53 mutations. T24 cells produce multiple cytokines, including granulocyte colony-stimulating factor (G-CSF), interleukin-6 (IL-6), and stem cell factor (SCF). The line is commonly used as a model for studying bladder cancer biology, oncogenic signaling pathways, cytokine regulation, and therapeutic responses in urothelial carcinoma.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.